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To investigate the pathogenic mechanism of ulcera-
tive colitis, a dextran sulfate sodium (DSS)-induced
acute colitis model was examined by serummetabo-
lomic analysis.Higher levelsof stearoyl lysophospha-
tidylcholine and lower levels of oleoyl lysophosphati-
dylcholine in DSS-treatedmice compared to controls
led to the identification of DSS-elicited inhibition
of stearoyl-CoA desaturase 1 (SCD1) expression in
liver. This decrease occurred prior to the symptoms
of acute colitis and was well correlated with elevated
expression of proinflammatory cytokines. Further-
more, Citrobacter rodentium-induced colitis and li-
popolysaccharide treatment also suppressed SCD1
expression in liver.Scd1 nullmiceweremore suscep-
tible toDSS treatment thanwild-typemice,whileoleic
acid feeding and in vivo SCD1 rescue with SCD1
adenovirus alleviated the DSS-induced phenotype.
This study reveals that inhibition of SCD1-mediated
oleic acid biogenesis exacerbates proinflammatory
responses to exogenous challenges, suggesting
that SCD1 and its related lipid species may serve as
potential targets for intervention or treatment of in-
flammatory diseases.
INTRODUCTION
The incidence of inflammatory bowel disease (IBD), including
Crohn’s disease and ulcerative colitis, is rising globally. In the
United States, IBD affects about 1.4 million people (Loftus,
2004). Genetic predisposition and environmental exposures
have been accepted as two major contributing factors in the ini-
tiation of IBD (Loftus, 2004; Schreiber and Hampe, 2000), while
autoimmune events, such as elevated production of proinflam-
matory cytokines and antibodies as well as increased activation
of immune cells, are the driving forces behind the progression ofIBD, leading to chronic inflammation, the destruction of intestinal
mucosa, and the manifestation of clinical symptoms (Levine and
Fiocchi, 2000). In spite of scientific advances in understanding
the pathogenesis of IBD, especially in the fields of pathology
and immunology (Xavier and Podolsky, 2007), many molecular
events related to the pathophysiology of IBD remain unknown.
Metabolomics, a rapidly evolving tool in systems biology, aims
to define small-moleculemetabolomes in biofluids, cells, tissues,
and organisms and to monitor the metabolic flux following
geneticmodification, pathophysiological changes, or exogenous
challenges (Nicholson et al., 1999; Griffin, 2006). Since multivar-
iate data analysis (MDA), the data processing platform of metab-
olomics, possesses the capacity to detect subtle changes in a
large data set, the potential application of metabolomics in the
diagnosis of disease (Brindle et al., 2002) and the characteriza-
tion of disease-related animal models (Dumas et al., 2006; Jones
et al., 2005) has been explored. However, the power of metabo-
lomics in establishing convincing biomarkers and identifying
novel molecular mechanisms has not been fully demonstrated.
To understand the pathogenesis of IBD and to explore new
therapeutic strategies, several IBD animal models based on
chemical treatment or geneticmodification have beendeveloped
(Byrne and Viney, 2006). Dextran sulfate sodium (DSS)-induced
acute colitis is one of the most widely used models because of
its robustness and reproducibility (Okayasu et al., 1990). The
influences of DSS treatment on the digestive tract and immune
systemhave been extensively examined (Cooper et al., 1993; Eg-
ger et al., 2000; Ni et al., 1996), while its impact on blood chem-
istry and the liver hasnot been fully explored. In thepresent study,
a liquid chromatography-mass spectrometry (LC-MS)-based
metabolomic approach was adopted to investigate this model.
A dramatic inhibitory effect of DSS treatment on stearoyl-CoA
desaturase 1 (SCD1) in the liver was identified through multivari-
ate model construction and structural elucidation of serum
biomarkers and further characterized as an early event prior to
the clinical symptoms. DSS-induced colitis was accelerated
in Scd1 null mice but attenuated by a high-oleic acid diet and
SCD1 overexpression, suggesting that SCD1-mediated oleic
acid biogenesis possesses a protective function against proin-
flammatory signaling.Cell Metabolism 7, 135–147, February 2008 ª2008 Elsevier Inc. 135
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Identification of SCD1 Inhibition by Metabolomic
Analysis of DSS-Elicited Changes in Mouse Serum
The occurrence of acute colitis after 7 day DSS treatment
was confirmed before conducting serum metabolomic analysis.
Both 2.5% and 5% DSS treatments significantly decreased
body weight and colon length (see Figure S1A available online)
and elicited severe diarrhea and rectal bleeding (Figure S1B).
Histological analysis revealed inflammation in mucosa, submu-
cosa, and muscularis propria with loss of crypts and surface
epithelia, as indicated by disease activity index (DAI) scores (Fig-
ure S1B). Overall, the pathological phenotype of the 5% DSS
group was more severe than in the 2.5% DSS group.
To examine the DSS-induced biochemical changes, an LC-
MS-based metabolomic analysis of deproteinized serum from
control andDSS-treatedmicewas performed. A two-component
model was constructed by a supervised partial least square dis-
criminant analysis (PLS-DA) using the values of mass, retention
time, and relative abundance of detected serum compounds
and further validated by a permutation method (Figure S1C).
Dose-dependent separation of the three mouse groups was ob-
served in the scores scatter plot and was mainly defined by the
first principal component (PC) of themodel (Figure 1A). Contribu-
tion of individual ions to the PCs was further examined in the
loadings scatter plot (Figure 1B). Among all detected serum
ions, one ion high in the DSS-treated samples (m/z = 524.372+
at 5.66 min) and two ions high in the controls (m/z = 522.355+
at 5.07 min and m/z = 520.339+ at 4.68 min) made the most
important contributions to the first PC. Tandem mass spectrom-
etry (MS/MS) fragmentation and accurate mass measure-
ments showed that all three compounds resembled each other
as revealed by the presence of 184.073+ (C5H15NO4P
+) and
104.107+ (C5H14NO
+) daughter ions (Figures S1D–S1F), charac-
teristic fragments formed by the cleavage of the phosphodiester
bond in the phosphocholine moiety (Pulfer and Murphy, 2003).
The appearance of ion 258.110+ (C8H21NO6P
+) further indicated
the existence of a glycerophosphocholine backbone and a
potential monoacyl moiety in all three compounds. Based on
the aforementioned structural information as well as the comple-
mentary nature of fragments 341.306+ (Figure S1D), 339.293+
(Figure S1E), and 337.271+ (Figure S1F) to the 184.073+
phosphocholine moiety, the structures of three lysophosphati-
dylcholines (LPCs) were determined as 1-stearoyl-sn-glycero-
3-phosphorylcholine (stearoyl-LPC; 18:0-LPC; accurate mass
of [M+H]+ = 524.3711), 1-oleoyl-sn-glycero-3-phosphorylcholine
(oleoyl-LPC; 18:1-LPC; [M+H]+ = 522.3554), and 1-linoleoyl-sn-
glycero-3-phosphorylcholine (linoleoyl-LPC; 18:2-LPC; [M+H]+ =
520.3398), respectively, and then confirmed by authentic stan-
dards. Because of their profound influence on the multivari-
ate model, the relative abundances of these three C18 acyl-LPC
species in the three mouse groups were compared. In a dose-
dependent manner, the relative abundance of saturated stearoyl-
LPC increased significantly,whereas both unsaturatedoleoyl-LPC
and linoleoyl-LPC decreased significantly after DSS treatment
(Figure 1C; Figure S1G).
The DSS-elicited imbalance between saturated and unsatu-
rated lipids, especially the increased ratio between stearoyl-LPC
and oleoyl-LPC, bears a striking resemblance to the phenotype136 Cell Metabolism 7, 135–147, February 2008 ª2008 Elsevier Incof Scd1 null mice, which are deficient in stearoyl-CoA desaturase
1 (SCD1), an endoplasmic reticulum (ER) enzyme responsible for
the biosynthesis of oleic acid (18:1) and palmitoleic acid (16:1)
from stearic acid (18:0) and palmitic acid (16:0), respectively
(Miyazaki et al., 2000).Western blot analysis ofmouse livermicro-
somes confirmed that SCD1 protein expression in liver was abol-
ished by DSS treatment (Figure 1D). Moreover, cytochrome P450
3A (CYP3A), another ER protein, was also significantly reduced,
while calnexin and GRP78, two constitutive proteins in the ER,
were not affected by the treatment, suggesting that DSS selec-
tively affects ER proteins (Figure 1D). Results from mRNA mea-
surement further revealed that SCD1 suppression occurred at
the transcriptional level (Figure 1E). To correlate the diminished
SCD1 expression with the decreased oleoyl-LPC and increased
stearoyl-LPC levels, serum metabolomic profiles of wild-type
and Scd1 null mice were compared. Scd1 null mice were clearly
separated from wild-type mice in the first PC of an unsupervised
principal components analysis (PCA) model (Figure 1F), and the
three top-ranking ions contributing to the separation were still
stearoyl-LPC (18:0-LPC), which is high in the Scd1 null mice,
and oleoyl-LPC (18:1-LPC) and linoleoyl-LPC (18:2-LPC), which
are high in the wild-type mice (Figure 1G). In addition, the ratio
of palmitoleoyl-LPC (16:1-LPC) to palmitoyl-LPC (16:0-LPC) in
both DSS-treated mice and Scd1 null mice was also dramatically
reducedcompared towild-typemice (datanot shown). Thus, all of
our observations supported the view that loss of hepatic SCD1
is the main cause of the altered balance between stearic acid-
derived lipid species and oleic acid-derived lipid species after
DSS treatment.
Correlation of SCD1 Suppression
with Proinflammatory Events
Dose-response experiments identified the inhibition of SCD1
expression after 7 day DSS treatment (Figures 1D and 1E). How-
ever, whether this dramatic suppression of gene expression was
a secondary effect or a direct response to DSS treatment was
still unknown. Thus, a time-course experiment was conducted
to examine the correlation between SCD1 expression and dis-
ease progression. The localized effects of 5% DSS on the colon,
including the reduction of colon length and histological damage,
appeared from day 1, while the clinical symptoms of acute coli-
tis, including body weight loss, diarrhea, and rectal bleeding,
did not become prominent until day 5 (Figures 2A and 2B). In
contrast to the mild symptoms in the first 3 days, SCD1 mRNA
and protein levels in liver were dramatically reduced from day
1 and almost completely suppressed on day 5 (Figures 2C and
2D). SCD1 inhibition in liver was further reflected by the progres-
sive decrease of oleoyl-LPC and the increase of stearoyl-LPC in
serum (Figure 2E). This rapid decrease of SCD1 expression and
function in liver was achieved without apparent hepatotoxicity as
indicated by serum aminotransferase activities (Figure 2F).
Sterol regulatory element-binding protein 1 (SREBP1), a tran-
scription factor controlling lipogenesis, is recognized as both
a regulator and an effector of SCD1 (Miyazaki et al., 2004; Tabor
et al., 1999). To determine the role of SREBP1 in DSS-induced
SCD1 suppression, SREBP1 expression in liver was examined.
Although DSS also reduced SREBP1 mRNA and protein in liver,
the decrease of SREBP1 proceeded in amuch less dramatic pat-
tern than the decrease of SCD1 (Figures S2A and S2B). Similarly,.
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Metabolomics of DSS-Induced ColitisFigure 1. Metabolomic Analysis of DSS-Induced Acute Colitis and Identification of SCD1 Inhibition
Mice were treated with 2.5% or 5% dextran sulfate sodium (DSS) in drinking water for 7 days.
(A) Scores scatter plot of partial least square discriminant analysis (PLS-DA) model of serum from the control (*, n = 8), 2.5% (+, n = 8), and 5% (A, n = 5) DSS-
treated groups. Metabolomic data were scaled by centering. The t[1] and t[2] values represent the scores of each sample in principal components 1 and 2,
respectively. The fitness (R2 value) and prediction power (Q2 value) of this two-component model are 0.85 and 0.52, respectively.
(B) Loadings scatter plot representing the correlation between individual serum ion (w*) and each sample group (c) in the first and second components of the
PLS-DA model.
(C) Relative abundance of three lysophosphatidylcholine (LPC) species in serum samples of control (n = 8), 2.5% (n = 8), and 5% (n = 5) DSS-treatedmice. The ion
intensity of stearoyl-LPC (18:0-LPC), oleoyl-LPC (18:1-LPC), and linoleoyl-LPC (18:2-LPC) in the serum of control mice was set arbitrarily as 1. Data are repre-
sented as mean value ± SD. *p < 0.01 versus control.
(D) Western blot measurement of SCD1, CYP3A, calnexin, and GRP78 protein in the livers of control, 2.5%, and 5% DSS-treated mice (n = 3).
(E) Real-time PCR measurement of Scd1 mRNA expression in the livers of control, 2.5%, and 5% DSS treated mice (n = 5). Data are represented as mean
value ± SD.
(F) Scores scatter plot of the principal components analysis (PCA) model (R2 = 0.78, Q2 = 0.37) of serum samples from wild-type and Scd1 null mice (n = 4).
(G) Loadings scatter plot of all detected serum ions in the PCA model. The p[1] and p[2] values represent the contributing weights of each ion to principal com-
ponents 1 and 2. The identities of three ions with the highest loading values are annotated in the plot.Cell Metabolism 7, 135–147, February 2008 ª2008 Elsevier Inc. 137
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Metabolomics of DSS-Induced ColitisFigure 2. Time-Course Responses to 5% DSS Treatment
During the 7 day 5% DSS treatment, liver and colon samples were collected at day 0, 1, 3, 5, and 7.
(A) Body weight and colon length of DSS-treated mice. Values are presented as the percentage of the body weight and colon length of untreated control mice at
day 0 (n = 5).
(B) Scores of diarrhea, bleeding, and histology. The scores were graded according to the disease activity index (DAI) criteria (n = 5).
(C) Real-time PCR measurement of Scd1 mRNA expression level in the livers of DSS-treated mice at day 0, 1, 3, 5, and 7 (n = 5).
(D) Western blot measurement of SCD1, CYP3A, calnexin, and GRP78 protein expression levels in the livers of DSS-treated mice at day 0, 1, 3, 5, and 7 (n = 3).
(E) Serum concentrations of stearoyl-LPC and oleoyl-LPC (18:0-LPC and 18:1-LPC, respectively) at day 0, 1, 3, 5, and 7 of DSS treatment (n = 5).
(F) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities (U/ml) of serum samples from DSS-treated mice at day 0, 1, 3, 5, and 7 (n = 3).
Serum samples from mice treated intraperitoneally with 400 mg/kg acetaminophen (APAP, 24 hr) were used as a positive control.
(G) Il1b mRNA expression level in livers and colons of DSS-treated mice at day 0, 1, 3, 5, and 7 (n = 5).
(H) Tnfa mRNA expression level in livers and colons of DSS-treated mice at day 0, 1, 3, 5, and 7 (n = 5).
Each data point or bar in this figure represents the mean value ± SD.138 Cell Metabolism 7, 135–147, February 2008 ª2008 Elsevier Inc.
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Metabolomics of DSS-Induced ColitisFigure 3. Suppression of SCD1 Expression
by Bacterially Induced Inflammatory Bowel
Disease and Endotoxin Treatment
Administration of Citrobacter rodentium and lipo-
polysaccharide (LPS) were performed as de-
scribed in Experimental Procedures.
(A) Overlaid chromatograms of stearoyl-LPC
and oleoyl-LPC (18:0-LPC and 18:1-LPC, respec-
tively) in serum samples of saline- and C. roden-
tium-treated mice. Ions within the 20 ppm range
of theoretical accurate masses of stearoyl-LPC
(524.3711+) and oleoyl-LPC (522.3554+) were ex-
tracted from a 10 min LC-MS run. The ion intensity
of stearoyl-LPC was set arbitrarily as 100%.
(B) Western blot measurement of SCD1, CYP3A,
calnexin, and GRP78 protein expression levels
in the livers of saline- and C. rodentium-treated
mice (n = 2).
(C) Real-time PCR measurement of Scd1 and
cyp3a11 mRNA expression levels in the livers of
saline- and C. rodentium-treated mice. Each bar
represents the mean value ± SD (n = 4).
(D) Western blot measurement of SCD1, CYP3A,
calnexin, and GRP78 protein expression levels in
the livers of saline- and LPS-treated mice (n = 3).the expression levels of acetyl-CoA carboxylase (Acc) and fatty
acid synthase (Fas), two SREBP1-targeting genes, were also
gradually reduced by DSS (Figures S2C and S2D). Since it has
been reported that Scd1 null mice have much lower SREBP1 ex-
pression than wild-type mice (Miyazaki et al., 2004), it is possible
that downregulation of SREBP1 might be a downstream event
of SCD1 inhibition instead of an upstream event. Moreover, be-
cause the regulation of SCD1 by insulin has been demonstrated
previously (Waters and Ntambi, 1994), serum insulin levels were
examined. The results indicated that DSS treatment has no sig-
nificant influence on insulin levels (Figure S2E).
Because production of proinflammatory cytokines is a critical
event in the initiation and progression of IBD, the relationship
between SCD1 suppression and cytokine expression was ex-
plored. Hepatic levels of interleukin 1b (IL-1b) and tumor necrosis
factor a (TNFa) were not significantly induced until day 3, al-
though their expression levels in colon rose rapidly from day 1
(Figures 2G and 2H). Overall, the inhibition of hepatic SCD1
expression was an early event in DSS-induced colitis, occurring
before the induction of proinflammatory cytokines in liver and the
appearance of systemic IBD symptoms.
Suppression of SCD1 Expression
by Bacterially Induced IBD and by Endotoxin
The size of the DSS molecule (35–44 kDa) used for inducing IBD
excludes its direct adsorption in the intestine, except for some
local uptake by macrophage-mediated phagocytosis in the co-
lonic mucosa (Kitajima et al., 1999). Therefore, the downregula-
tion of SCD1 expression in liver was probably achieved by sig-
nals derived from the gut instead of a direct effect of DSS on
the liver. Since DSS treatment can significantly affect the bacte-
rial population in the colon and also inflict damage to the epithe-
lial layer (Okayasu et al., 1990), it is possible that signals from
disrupted intestinal microflora may play a role in SCD1 inhibitionin liver. To examine this hypothesis, a bacterially induced IBD
model was adopted. After infection with Citrobacter rodentium,
a rodent-specific pathogenic bacterium (Higgins et al., 1999),
colonic hyperplasia represented by dramaticmucosal thickening
developed, and other IBD symptoms including diarrhea, slight
rectal bleeding, and body weight loss were observed (data not
shown). The serum oleoyl-LPC level was dramatically reduced
following C. rodentium infection (Figure 3A), corresponding to
the diminished protein and gene expression of hepatic SCD1
(Figures 3B and 3C). Furthermore, lipopolysaccharide (LPS)
treatment also abolished SCD1 expression in liver (Figure 3D),
suggesting a potential contribution by bacterial endotoxins to
the DSS- and C. rodentium-elicited SCD1 inhibition.
Acceleration of DSS-Induced Acute
Colitis in Scd1 Null Mice
To examine the role of SCD1 in DSS-induced colitis, Scd1 null
mice were challenged with DSS. Compared to wild-type mice,
Scd1 null mice were much more susceptible to DSS, as indi-
cated by increased body weight loss (Figure 4A), shorter colon
length (Figure 4B), and more severe diarrhea (Figure 4C) and
rectal bleeding (Figure 4D). These results suggest that SCD1 in-
hibition might be not only a passive event following DSS treat-
ment but a contributing factor to the progression of colitis.
Attenuation of DSS-Induced Acute Colitis and
Proinflammatory Signaling by a High-Oleic Acid Diet
A direct consequence of SCD1 inhibition is the imbalance
between saturated LPCs and monounsaturated LPCs in serum,
as shown inDSS treatment andScd1 nullmice (Figure 1; Figure 2;
Figure 3). Previous studies on palmitoyl-LPC (16:0-LPC) and
stearoyl-LPC (18:0-LPC) have largely defined saturated LPCs
as proinflammatory (Asaoka et al., 1992; Huang et al., 2005)
and atherogenic phospholipids (Wu et al., 1998), consistentCell Metabolism 7, 135–147, February 2008 ª2008 Elsevier Inc. 139
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was accompanied by a simultaneous increase in the serum
stearoyl-LPC level. However, the significance of reduced serum
oleoyl-LPC levels in the pathogenesis of acute colitis was still un-
clear. One interesting observation, reported in two independent
studies on LPCs, is that IL-1b production from monocytes (Liu-
Wu et al., 1998) and microglia (Stock et al., 2006) is significantly
induced by both palmitoyl-LPC and stearoyl-LPC, but not by
monounsaturated oleoyl-LPC, suggesting a potential functional
difference between saturated LPCs and unsaturated LPCs. To
examine this hypothesis, the response of mice on a high-oleic
acid diet to 2.5% DSS treatment was compared with that of
mice on a control diet. Diarrhea and rectal bleeding appeared
on day 2 in the control group but did not become prominent
in the high-oleic acid group until day 4 and day 5 of DSS treat-
ment, respectively (Figure 5A). Microscopic examination of colon
tissues indicated that high-oleic acid feeding alone did not alter
colon histology in comparison to the control group (Figure 5B).
However, DSS-induced colon damage in mice on the high-oleic
acid diet (histology DAI 2.15 ± 0.55) was much less severe than
that in mice on the control diet (histology DAI 3.85 ± 0.66) after
a 7 day treatment, and total loss of colonic crypts and surface
epithelia in the control diet group was partially reversed by the
high-oleic acid feeding (Figure 5B).
Serum metabolomics showed a clear separation of the four
mouse groups in a PCA model, in which the first PC determined
the responses to DSS treatment while the second PC separated
high-oleic acid feeding from control feeding (Figure 5C). As ex-
pected, oleoyl-LPC and stearoyl-LPC were the two ions with
the greatest contribution to the first PC in the loadings scatter
plot, while the higher abundances of linoleoyl-LPC and palmi-
toyl-LPC in mice on the control diet helped define the second
PC (Figure 5D). High-oleic acid feeding raised the serum
Figure 4. Acceleration of DSS-Induced
Colitis in Scd1 Null Mice
Pathological symptoms and DAI scores were
compared among four groups of mice, including
untreated wild-type (n = 3), 2% DSS-treated
wild-type (n = 7), untreated Scd1 null (n = 3), and
2% DSS-treated Scd1 null mice (n = 6).
(A) Body weight during 7 day DSS treatment.
Values are presented as the percentage of day
0 body weight.
(B) Colon length after 7 day DSS treatment. Values
are presented as the percentage of untreated
control colon length at day 7.
(C) Diarrhea scores during 7 day DSS treatment.
(D) Rectal bleeding scores during 7 day DSS treat-
ment.
Each data point or bar in this figure represents the
mean value ± SD.
oleoyl-LPC level to about 2.5-fold of the
level in the untreated control group
(Figure 5E). In fact, after 7 days of DSS
treatment, the serum oleoyl-LPC level in
the high-oleic acid groupwas still compa-
rable to its level in the untreated control
group. However, it should be noted that
the high-oleic acid feeding did not alter the basal expression level
of hepatic SCD1 or the inhibitory effects of DSS treatment on
SCD1, as shown by the gene expression level of Scd1 in liver
(Figure 5F) and the fact that serum oleoyl-LPC levels in the
high-oleic acid group were still significantly decreased following
DSS treatment (Figure 5G). This result further confirmed that the
regulation of serum oleoyl-LPC levels following DSS treatment
is a downstream event of SCD1 activity. Moreover, DSS-induced
Il1b gene expression in colon was significantly reduced by high-
oleic acid feeding (Figure 5G). Similarly, DSS-elicited increase
of serum IL-1b levels was also partially reversed by high-oleic
acid feeding (Figure 5H). Overall, higher levels of serum oleoyl-
LPCcorresponded to reducedproduction of proinflammatory cy-
tokines andattenuatedprogressionofDSS-inducedacute colitis.
Attenuation of DSS-Induced Acute Colitis
by SCD1 Overexpression
Both the susceptibility of Scd1 null mice to DSS (Figure 4) and
the resistance of mice fed a high-oleic acid diet (Figure 5) sug-
gested that SCD1 might possess a protective function against
proinflammatory signals. To validate this hypothesis, SCD1
was overexpressed by adenovirus-mediated in vivo transfection.
Compared to mice transfected with control adenovirus, the initi-
ation and progression of clinical symptoms of DSS-induced
colitis were much more delayed in mice transfected with SCD1
adenovirus (Ad-SCD1) during a 7 day 5% DSS treatment, as in-
dicated by body weight, colon length, and the DAI scores of rec-
tal bleeding and diarrhea (Figures 6A–6D). Examination of SCD1
protein levels in liver showed that Ad-SCD1 mice not only had
higher basal SCD1 expression than control mice but also sus-
tained higher SCD1 levels even after 5 days of DSS treatment
(Figure 6E). The protective effect of SCD1 transfection was
further reflected in the fact that at day 5 of DSS treatment,140 Cell Metabolism 7, 135–147, February 2008 ª2008 Elsevier Inc.
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higher serum oleoyl-LPC levels than corresponding controls
(Figure 6F).
DISCUSSION
Although Crohn’s disease and ulcerative colitis, two subtypes
of IBD, are mainly localized ailments, pathological phenotypes
of IBD are not limited to the digestive tract. Clinical data have
suggested that IBD can inflict severe damage to the hepatobili-
ary system (Desmet andGeboes, 1987). For example, two prom-
inent side effects of IBD are the high incidence of both primary
sclerosing cholangitis (Broome and Bergquist, 2006) and abnor-
mal liver function (Mendes et al., 2007). However, the underlying
mechanism is still largely unknown, even after extensive patho-
logical and immunological investigations. To obtain further
insights into the etiology and clinical symptoms of IBD, a metab-
olomic approach was adopted in this study to examine the IBD-
related biochemical changes. Serum, as the major destination
for small molecules originating from the liver, was used as the
sample. DSS-induced acute colitis was chosen as the IBD
animal model because of its robustness and resemblance to hu-
man IBD regarding the disruption of the colonic epithelial layer
and the progressive immune and inflammatory responses (Ar-
seneau et al., 2000; Podolsky, 2000). Serum metabolomic anal-
ysis revealed that DSS treatment shifted the balance between
saturated LPCs and monounsaturated LPCs in serum. Since
SCD1 is the sole enzyme responsible for the biogenesis of
both oleic acid and palmitoleic acid (twomajormonounsaturated
fatty acids in vivo) and since the liver is a major site of biogenesis
for serum LPCs (Baisted et al., 1988; Sekas et al., 1985), this
change in the serum lipid profile was subsequently attributed
to the rapid and complete inhibition of Scd1 gene expression
in liver. In fact, the results from this study indicated that the ratio
between serum stearoyl-LPC and serum oleoyl-LPC is a suffi-
cient in vivo biomarker of SCD1 activity. Overall, the identifica-
tion of SCD1 inhibition in this study demonstrates the power of
LC-MS-basedmetabolomics as a tool for unraveling disease-as-
sociated biochemical events and their underlying mechanisms.
The combination of high-resolution chromatography and accu-
rate mass measurement can function as an efficient technical
platform for defining the metabolomic profile of complex bioma-
trices.
Despite the insights obtained from this metabolomics-based
study, it remains to be determined how DSS treatment, which
is thought to be a localized event in thedigestive tract, can sodra-
matically affect SCD1 enzyme levels in the liver. It is known that
DSS treatment has a significant influence on the microbial popu-
lation in the intestine (Okayasu et al., 1990), which in turn can
affect the initiation and progression of inflammatory responses
(Lupp et al., 2007). To examine the potential role of bacteria
in the regulation of hepatic SCD1 expression, a C. rodentium-
induced IBD model was further adopted in this study. Similar
to the DSS model, C. rodentium infection led to the downregula-
tion of SCD1 in liver and the dramatic decrease of oleoyl-LPC
species in serum, even though the phenotype and symptoms
of this model were different from those of the DSS model in
many aspects. Furthermore, intraperitoneal injection of endo-
toxin also abolished hepatic SCD1 expression. Therefore, it ishighly likely that disruption of intestinal microflora and the
release of endotoxins following DSS treatment contribute to
the inflammatory responses, and the downregulation of SCD1
expression should therefore be considered a general event in
IBD instead of a DSS-specific event (Figure 7). Interestingly,
SCD1 is not the sole enzyme in the ER that is affected by DSS,
C. rodentium, and LPS treatments. Members of the cytochrome
P450 enzyme family, including CYP3A in this study, are also sig-
nificantly downregulated by DSS (Masubuchi and Horie, 2004),
bacteria (Richardson et al., 2006), and endotoxins (Morgan,
1989). As direct downstream targets of endotoxins and bacterial
infection, proinflammatory cytokines, such as TNFa and interleu-
kins, can also suppress the expression of ER enzymes (Mon-
shouwer et al., 1996), including SCD1 (Weiner et al., 1991). Since
IL-1b expression and TNFa expression in colon were dramati-
cally induced from day 1 of DSS treatment (Figures 2G and
2H), it is likely that portal vein delivery of proinflammatory cyto-
kines from the colon, as revealed by the elevated IL-1b levels
in serum, may contribute to suppression of SCD1 expression
in liver. Overall, SCD1 inhibition following DSS, C. rodentium,
and LPS treatments should be considered the consequence of
multiple proinflammatory events. The exact roles of bacteria,
endotoxins, and cytokines in these events remain to be investi-
gated.
LPCs, which mainly originate from the phospholipase A2
(PLA2)-mediated hydrolysis of phosphatidylcholine and lecithin-
cholesterol acyltransferase-catalyzed transesterification, are
major lipid species in serum (Croset et al., 2000; Glomset,
1968). Under conditions of normal homeostasis, the bioactivities
of serum LPCs are suppressed by forming complexes with albu-
min and lipoproteins (Croset et al., 2000). However, under patho-
logical conditions, the serum concentrations of free LPCs can be
significantly elevated due to the accumulation of LPCs (Mehta
et al., 1990; Okita et al., 1997; Sasagawa et al., 1999; Sobel
et al., 1978) and the depletion of albumin in serum (Liao et al.,
1986), leading to higher LPC-related bioactivities. It has been re-
ported that ovarian cancer patients have higher levels of serum
palmitoyl- and stearoyl-LPC and lower levels of serum oleoyl-
and linoleoyl-LPC compared to healthy subjects (Okita et al.,
1997), which resembles the LPC profile produced by DSS and
C. rodentium infection. Therefore, future studies on the serum
metabolome of human IBD and cancer patients should provide
more information on the clinical relevance of SCD1 inhibition.
As for the role of individual LPCs in the pathogenesis of colitis,
the correlation between increased concentrations of palmitoyl-
and stearoyl-LPC and elevated levels of IL-1b and TNFa in this
study is consistent with previous in vitro observations (Liu-Wu
et al., 1998; Stock et al., 2006; Takabe et al., 2004) and further
suggests that saturated LPCs can promote the release of proin-
flammatory cytokines in vivo and exacerbate the pathological
signs of inflammation. On the other hand, monounsaturated
LPCs, especially oleoyl-LPC, are potentially protective since the
low serum oleoyl-LPC levels in Scd1 null and DSS-treated mice
correspondedwith susceptibility to acute colitis and the progres-
sion of inflammation whereas the high serum oleoyl-LPC levels
achieved by the high-oleic acid diet and SCD1 overexpression
wereassociatedwith resistance toDSS.Thisconclusion is further
supported by previous observations that oleic acid-derived lipids
are significantly decreased in the trinitrobenzenesulfonic acidCell Metabolism 7, 135–147, February 2008 ª2008 Elsevier Inc. 141
Cell Metabolism
Metabolomics of DSS-Induced ColitisFigure 5. Attenuation of DSS-Induced Colitis by a High-Oleic Acid Diet
Pretreatment and treatment of four groups ofmice, including control, high-oleic acid diet (OA), 2.5%DSS treatment (DSS), and high-oleic acid diet with 2.5%DSS
treatment (OA+DSS), were performed as described in Experimental Procedures.
(A) Rectal bleeding and diarrhea scores during 7 day DSS treatment.
(B) Representative images of hematoxylin and eosin-stained colon tissues from the four groups of mice after 7 day DSS treatment.
(C) Scores scatter plot of a PCAmodel (R2 = 0.77, Q2 = 0.28) of serum samples frommice on a control diet (control, n = 10), mice on a control diet with 2.5% DSS
treatment (DSS, n = 9; one died before day 7), mice on a high-oleic acid diet (OA, n = 10), and mice on a high-oleic acid diet with 2.5% DSS treatment (OA+DSS,
n = 10). Metabolomic data were scaled by centering.
(D) Loadings scatter plot of all detected serum ions in the PCA model. The identities of four ions with the highest loading values are annotated in the plot.142 Cell Metabolism 7, 135–147, February 2008 ª2008 Elsevier Inc.
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Metabolomics of DSS-Induced Colitis(TNBS)-induced acute colitis model (Nieto et al., 2002) and that
supplemental olive oil in the diet attenuates DSS-induced toxicity
(Camuescoetal., 2005). It is possible that oleoyl-LPC,whichdoes
not induce the release of proinflammatory cytokines from im-
mune cells (Liu-Wu et al., 1998; Stock et al., 2006), might counter
the cytokine-inducing effect of saturated LPCs by competitively
blocking their binding to potential LPC receptors in endothelial
cells (Lum et al., 2003). Therefore, instead of concluding that all
(E) Relative abundance of serum stearoyl-LPC (18:0-LPC) and oleoyl-LPC (18:1-LPC) in the four groups of mice. The ion intensity of stearoyl-LPC and oleoyl-LPC
in the control mice was set arbitrarily as 1.
(F) Real-time PCR measurement of Scd1 mRNA expression level in the livers of the four groups of mice (n = 5).
(G) Il1b mRNA expression level in colons of the four groups of mice (n = 5).
(H) IL-1b concentration in serum samples from the four groups of mice (n = 4).
Each data point or bar in this figure represents the mean value ± SD.
Figure 6. Attenuation of DSS-Induced Colitis by SCD1 Overexpression
Pretreatment and treatment of four groups of mice, including mice transfected with control adenovirus (Ad, n = 5), mice transfected with control adenovirus and
treated with 5% DSS (Ad+DSS, n = 5), mice transfected with SCD1 adenovirus (Ad-SCD1, n = 10), and mice transfected with SCD1 adenovirus and treated with
5% DSS (Ad-SCD1+DSS, n = 10), were performed as described in Experimental Procedures.
(A) Body weight during 7 day DSS treatment. Values are presented as the percentage of day 0 body weight.
(B) Colon length after 7 day DSS treatment. Values are presented as the percentage of untreated control colon length at day 7.
(C) Diarrhea scores during 7 day DSS treatment.
(D) Rectal bleeding scores during 7 day DSS treatment.
(E) Western blot measurement of SCD1, CYP3A, calnexin, and GRP78 protein expression levels in livers of DSS-treated mice at day 5 of treatment (n = 3).
(F) Relative abundance of serum oleoyl-LPC (18:1-LPC) and stearoyl-LPC (18:0-LPC) in the four groups of mice. The ion intensity of oleoyl-LPC and stearoyl-LPC
in the control mice was set arbitrarily as 1 (*p < 0.01).
Each data point or bar in this figure represents the mean value ± SD.Cell Metabolism 7, 135–147, February 2008 ª2008 Elsevier Inc. 143
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Metabolomics of DSS-Induced ColitisLPCs are proinflammatory, as in previous studies using saturated
LPCs for chemical treatments (Huang et al., 2005; Lum et al.,
2003; Ousman and David, 2000; Takabe et al., 2004), the results
from our study suggest that there are functional differences
among LPC species with regard to the activation of the immune
system. In addition to LPCs, free fatty acids and their other deriv-
atives can also mediate the immune responses (Zurier, 1993).
For example, nitrated oleic acid has been identified as an endog-
enous ligand of peroxisome proliferator-activated receptor
g (PPARg), an important transcription factor in anti-inflammatory
signaling (Baker et al., 2005). However, the exact role of oleic
acid, nitrated oleic acid, and oleoyl-LPC in maintaining the ho-
meostasis of the immunesystemand the underlyingmechanisms
of inflammation still requires further study. Overall, the results of
this study support a model in which SCD1 plays a suppressive
role in proinflammatory signaling by converting saturated fatty
acids to monounsaturated fatty acids (Figure 7). This conclusion
provides a possible mechanistic explanation for the widely re-
ported observation that consumption of unsaturated fat, such
as the olive oil-rich Mediterranean diet, has anti-inflammatory
benefits for diseases associated with inflammation, such as car-
diovascular disease, rheumatoid arthritis, and IBD (Alarcon de
la Lastra et al., 2001) while the consumption of saturated fat is
largely proinflammatory (Nicholls et al., 2006).
In summary, LC-MS-based metabolomic analysis identified
a dramatic inhibition of SCD1 expression, potentially mediated
by endotoxins and cytokine signaling, as an early event in DSS-
induced acute colitis. The accumulation of saturated LPCs
through the inhibition or deficiency of SCD1 exacerbated the im-
mune response, whereas the increase ofmonounsaturated lipids
through dietary supplementation and SCD1 overexpression
attenuated DSS-induced inflammation, suggesting that SCD1
functions as a suppressive regulator of the immune systemunder
normal homeostasis (Figure 7). Uncovering pathogenicmodifica-
tions of the transcriptome and proteome through a metabolomic
Figure 7. Role of SCD1 and Its Related Lipid
Species in DSS-Induced Proinflammatory
Signaling
Red represents proinflammatory signaling; green
represents anti-inflammatory signaling. Solid lines
indicate known pathways; the dashed line denotes
a putative pathway.
approach offers great promise for the use




DSS (35–44 kDa)was purchased fromMPBiomed-
icals. Lysophosphatidylcholines were obtained
from Avanti Polar Lipids, and other reagents were
obtained from Sigma-Aldrich. For the oleic acid
supplementation experiment, an AIN93M purified
diet containing 40 g/kg soybean oil was used as
the control diet, and a modified AIN93M diet con-
taining 30 g/kg oleic acid and 10 g/kg soybean oil
was used as the high-oleic acid diet (Dyets, Inc.).
Mice were acclimated to the AIN93M control diet or high-oleic acid diet for
1 week prior to DSS treatment.
DSS-Induced Colitis and Tissue Evaluation
Male C57BL/6mice, 5 to 8weeks old, were purchased fromCharles River Lab-
oratories. Scd1 null mice were described previously (Miyazaki et al., 2001).
Maintenance and handling were in accordance with animal study protocols
approved by the NCI Animal Care and Use Committee. Mice were adminis-
tered 2%–5% (w/v) DSS in drinking water. Daily changes in body weight and
pathological signs of colitis, including rectal bleeding, diarrhea, and bloody
stool, were assessed by an experienced pathologist and reported as the dis-
ease activity index (DAI) on a scale from 0 to 4. Serum samples were collected
by retro-orbital bleeding at the end of DSS treatment. Liver and colon samples
were harvested immediately following CO2 euthanization. Formicroscopic and
macroscopic examination of colon damage, colons were opened longitudi-
nally, flushed with PBS, and fixed in 10% buffered formalin. After colon length
measurement, colons were Swiss rolled and processed in paraffin. Colon sec-
tions stained with hematoxylin and eosin were scored according to the histo-
logical criteria of colitis (Cooper et al., 1993). Liver function was evaluated by
measuring serum aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT) activities (Catachem).
Bacterially Induced IBD Model and Endotoxin Treatment
Establishment of the bacterially induced IBD model was described previously
(Richardson et al., 2006). Briefly, C3H/HeOuJ mice were infected with 2.0 3
108 colony-forming units of C. rodentium (ATCC) in saline by oral gavage.
The control group was administered saline by gavage. Mice were sacrificed
after apparent clinical symptoms of IBD were observed. Serum, liver, and co-
lon samples were collected for further analysis. For endotoxin treatment, two
groups of C57BL/6 mice were administered saline or 4 mg/kg LPS in saline by
intraperitoneal injection and sacrificed 24 hr later for liver collection.
LC-MS Analysis of Mouse Serum
Serum samples were mixed with 20 volumes of 66% aqueous acetonitrile and
centrifuged at 18,000 3 g for 10 min to remove protein and particulates. For
LC-MS analysis, a 5 ml aliquot was injected into aWaters UPLC-QTOFMS sys-
tem. An Acquity UPLC BEH C18 column (Waters) was used to separate serum
metabolites at 35C. The mobile phase flow rate was 0.5 ml/min, with a gradi-
ent ranging from 5% to 99% aqueous acetonitrile containing 0.1% formic acid
over a 10 min run. The QTOF Premier mass spectrometer was operated in144 Cell Metabolism 7, 135–147, February 2008 ª2008 Elsevier Inc.
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Metabolomics of DSS-Induced Colitisthe positive electrospray ionization (ESI) mode. Capillary voltage and cone
voltage were maintained at 3 kV and 20 V, respectively. Source temperature
and desolvation temperature were set at 120C and 350C, respectively. Nitro-
gen was used as both cone gas (50 l/hr) and desolvation gas (600 l/hr), and
argon was used as collision gas. For accurate mass measurement, the
mass spectrometer was calibrated with sodium formate solution (range m/z
100–1000) and then monitored by intermittent injection of the lock mass sulfa-
dimethoxine ([M+H]+ = 311.0814 m/z) in real time. Mass chromatograms and
mass spectral data were acquired by MassLynx software (Waters) in cen-
troided format. The structures of serum biomarkers were elucidated by MS/
MS fragmentation with collision energies ranging from 15 to 35 eV. Serum con-
centrations of stearoyl-LPC and oleoyl-LPC were quantified using QuanLynx
(Waters). Standard curves of both LPCs were linear in the range of 0.5–20 mM
(r2 > 0.95).
Data Processing and Multivariate Data Analysis
Chromatographic and spectral data of serum samples were processed using
MarkerLynx (Waters) to generate a multivariate data matrix by centroiding,
integration, normalization, and deconvolution. The data matrix was further
exported into SIMCA-P+ software (Umetrics) and transformed by an appropri-
ate scaling technique for model construction. Major latent variables in the data
matrix, represented as principal components, were generated by principal
components analysis (PCA) and partial least square discriminant analysis
(PLS-DA) and described in a scores scatter plot. Serum biomarkers were iden-
tified by analyzing ions in the loadings scatter plot.
Western Blot Analysis
Microsomes, whole-cell lysates, and nuclear extracts of mouse liver were pre-
pared following standard procedures. Targeted proteins were detected using
corresponding antibodies, including CYP3A (mAb 2-13-1) (Park et al., 1986),
SCD1, calnexin, GRP78, SREBP1, and GAPDH (Santa Cruz Biotechnology).
RNA Analysis
Quantitative real-time PCR (qPCR) was performed using SYBR green PCR
master mix (Superarray) in an ABI Prism 7900HT Sequence Detection System
(Applied Biosystems). Primer sequences are listed in Table S1. Expression
levels of targeted genes were normalized to b-actin.
Insulin and IL-1b Analysis
Serum insulin levels were measured by radioimmunoassay (RIA) (Linco Re-
search). Serum IL-1b levels were determined by enzyme-linked immunosor-
bent assay (ELISA) (R&D Systems).
In Vivo Overexpression of SCD1 by Adenovirus-Mediated
Transfection
Adenovirus expressing rat SCD1 (Ad-SCD1) was kindly provided by V.I. Zannis
(Boston University), and control adenovirus was kindly provided by S. Kimura
(National Cancer Institute). Construction of Ad-SCD1 using pAdTrackCMV
vector was described previously (Drosatos et al., 2007). Ad-SCD1 was ampli-
fied in QBI293 cells and purified by two cesium chloride ultracentrifugation
steps followed by dialysis and titration. For in vivo transfection, male C57BL/6
mice were injected with 23 109 plaque-forming units of control adenovirus or
Ad-SCD1 per mouse. Second and third injections were conducted at the third
and sixth day of DSS treatment.
Statistics
Experimental values are expressed as mean ± SD. Statistical analysis was
performed by two-tailed Student’s t test for unpaired data, with p < 0.05 con-
sidered statistically significant.
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Supplemental Data include one table, Supplemental References, and two fig-
ures and can be found with this article online at http://www.cellmetabolism.
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